Ipamorelin is a growth hormone secretagogue and selective ghrelin receptor agonist
Clinical data suggest this produces greater average weight loss compared to semaglutide alone
This broad receptor distribution underlies the pleiotropic research profile of GLP-1 from appetite and reward behaviour regulation in the central nervous system, to cardioprotective effects in cardiac tissue, to anti-inflammatory and immunomodulatory activity in immune cell models
That creates risk because product purity, dosing accuracy, storage, sterility, and ingredient quality may vary
In normal weight loss, non-fat tissues (lean mass), including muscle, are also decreased in size
A progressive decrease in body weight was also observed for up to 3 years in exenatide-treated patients [46,48]